Less Ads, More Data, More Tools Register for FREE

Pin to quick picksCambridge Cog Regulatory News (COG)

Share Price Information for Cambridge Cog (COG)

Share Price is delayed by 15 minutes
Get Live Data
37.00    0.00 (0.00%)
Bid:
35.00
Ask:
39.00
Spread: 4.00 (11.429%)
Market Cap: £17.23m
COG Live PriceLast checked at - London Stock Exchange

Intraday Cambridge Cog Share Chart

AGM Statement

27 May 2015 07:00

RNS Number : 2898O
Cambridge Cognition Holdings PLC
27 May 2015
Β 

Β 

Cambridge Cognition Holdings Plc

('Cambridge Cognition' or the 'Company')

Β 

AGM Statement

Β 

Cambridge Cognition Holdings plc, (AIM: COG), which specialises in computerised neuropsychological tests including those enabling the early detection of dementia, will hold its Annual General Meeting today at 10.00am at the offices of finnCap, 60 New Broad Street, London, EC2M 1JJ.

Β 

At the meeting Nick Kerton, Chief Executive Officer, will provide shareholders with the following update:

Β 

As I outlined in our Preliminary Results statement our financial performance remains in line with market expectations.

Β 

The contribution from our clinical trials and academic businesses continued to grow in the first quarter. In particular the enlarged US sales team offers an opportunity to enhance both clinical and academic sales in North America and we already have a healthy pipeline of contracts in the safety and tolerability trial space that we expect to convert over the remainder of the year.

Β 

The return to profitability in our clinical trials and academic businesses enables us to increase investment in our early stage healthcare technology business which bodes well for the future prospects of the Company.

Β 

Β 

Enquiries:

Β 

Cambridge Cognition Holdings plc

www.cambridgecognition.com

Nick Kerton, Chief Executive Officer

Tel: 01223 810 700

Nick Walters, Chief Financial Officer

Β 

Β 

Β 

finnCap Ltd (Nomad and Broker)

Tel: 020 7220 0500

Geoff Nash/Simon Hicks

(Corporate Finance)

Malar Velaigam

(Corporate Broking)

Β 

Β 

Walbrook PR Ltd

Tel: 020 7933 8780 or camcog@walbrookpr.com

Paul McManus

Mob: 07584 391 303

Lianne Cawthorne

Mob: 07584 391 303

Β Β Β 

Β 

Β 

Β 

About Cambridge Cognition

Cambridge Cognition is a world leading provider of computerised cognitive assessment products.Β The company's range of touch-screen CANTABβ„’ neuropsychological tests, highly validated over one thousand peer-reviewed publications, are used by both academic scientists in their research, and clinical researchers in the pharmaceutical industry, to maximise knowledge of cognitive function. In addition, the company is committed to broadening the access to this technology and is developing clinical healthcare products under the Cantab mobile brand, to improve the monitoring, management and maintenance of cognitive health and wellbeing. Using these assessments, clinicians can identify and stratify patients so that patient referrals are accurate and efficient, enablingΒ health and social care providers to deliver more effective advice, treatments and care - leading to better outcomes for patients and their families.

This information is provided by RNS
The company news service from the London Stock Exchange
Β 
END
Β 
Β 
AGMPKADPABKDAPB
Date   Source Headline
30th Jun 20207:00 amRNSTrading Update
23rd Jun 20204:18 pmRNSHolding(s) in Company
9th Jun 20207:00 amRNSGrant of Options
5th Jun 20207:00 amRNSCapital Markets Showcase
27th May 20207:00 amRNSOver £1 million of New Contract Wins
6th May 20206:11 pmRNSHolding(s) in Company
6th May 202012:15 pmRNSHolding(s) in Company
5th May 20207:00 amRNSPreliminary Results - Year ended 31 December 2019
29th Apr 20202:19 pmRNSNotice of Results
14th Apr 20207:00 amRNSHolding(s) in Company
14th Apr 20207:00 amRNSHolding(s) in Company
23rd Mar 20204:00 pmRNSDelayed Preliminary Results
19th Mar 20207:00 amRNSAward of Innovative Medicines Initiative grant
17th Mar 20207:00 amRNS£1.37 million of new eCOA contracts
10th Mar 20204:15 pmRNSHolding(s) in Company
10th Mar 20204:15 pmRNSHolding(s) in Company
9th Mar 202012:46 pmRNSResult of General Meeting
19th Feb 20207:01 amRNSFundraising to raise £1.4m & Notice of GM
19th Feb 20207:00 amRNSTrading Update and Notice of Results
10th Jan 20203:54 pmRNSHolding(s) in Company
25th Nov 20197:00 amRNSCambridge Cognition expands eCOA and wins contract
31st Oct 20194:17 pmRNSGrant of Options
29th Oct 20197:00 amRNSHolding(s) in Company
25th Oct 20197:00 amRNSAlzheimer's drug potential for Cambridge Cognition
26th Sep 201912:15 pmRNSDirector/PDMR Shareholding
23rd Sep 201910:42 amRNSDirector/PDMR Shareholding
19th Sep 20197:00 amRNSInterim Results
30th Aug 20194:59 pmRNSHolding(s) in Company
29th Aug 20192:20 pmRNSHolding(s) in Company
27th Aug 20197:00 amRNSTrading Update
14th Aug 201910:10 amRNSDr. Nick Kerton
12th Aug 20197:00 amRNSExpansion in Chinese market
22nd Jul 20197:00 amRNSNotice of Results
19th Jul 20197:00 amRNSNew Commercial Partnership for NeuroVocalix
1st Jul 20197:00 amRNSAppointment of Non-Executive Director
11th Jun 20197:00 amRNSCapital Markets Day
23rd May 20192:35 pmRNSResult of AGM and Board Changes
1st May 20197:00 amRNSPosting of Annual Report & Notice of AGM
25th Apr 20197:00 amRNSBoard Changes
17th Apr 20197:00 amRNSGrant of Options
19th Mar 20197:00 amRNS£1.3m digital health contract win
14th Mar 20198:54 amRNSHolding(s) in Company
14th Mar 20197:00 amRNSHolding(s) in Company
12th Mar 20195:23 pmRNSDirector/PDMR Shareholding
12th Mar 201911:59 amRNSHolding(s) in Company
7th Mar 20197:02 amRNSAppointment of Chief Operating Officer
7th Mar 20197:01 amRNSFundraising to raise £2.5 million
7th Mar 20197:00 amRNSPreliminary Results
31st Jan 20197:00 amRNSFirst Partnership in India and New Product Launch
19th Dec 20187:00 amRNSTrading update and notice of results

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.